Media registration
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO Media Policy which applies to all ESMO events.
To apply for media accreditation, please fill out the form available here:
Complete the Media Registration Form
Media registration in advance is strongly recommended. Further information for press representatives will be made available closer to the event.
Opening press conference
The ESMO2021 Opening Press Conference will be held via Zoom on Thursday, 9 September, 14:00-14:45 CEST.
Moderator:
- Antonio Passaro, IEO - Istituto Europeo di Oncologia, Italy – ESMO2021 Press Officer
Panellists:
- Solange Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Switzerland – ESMO President
- Pasi Jänne, Dana Farner, USA - ESMO2021 Scientific Co-Chair
- Manola Bettio, European Commission – Joint Research Centre, Ispra, Italy (abstract 1501O_PR)
- Alessio Cortellini, University of l’Aquila, Italy – (abstract 1560O_PR)
To participate in the Opening Press Conference, media representatives must be accredited for the Congress, prior to Monday 6 September.
Publication schedule for accepted abstracts
Abstracts |
Release on ESMO website |
|---|---|
|
Abstracts accepted as:
|
Monday, 13 September 2021 |
|
Abstracts and late-breaking abstracts accepted as:
|
Friday, 17 September 2021 |
|
Abstracts and late-breaking abstracts accepted as:
|
Saturday, 18 September 2021 |
Abstracts and late-breaking abstracts with a different release schedule or with suffix _PR |
See below paragraphs for details |
Embargo policy
Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above.
Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official programme session during which the study is presented.
Important Note: For the abstracts and late-breaking abstracts listed in the two below paragraphs, changes in embargo rules may apply (see details).
Abstracts selected for press releases (suffix _PR)
Abstract ID |
Title |
Embargo lift |
|---|---|---|
1501O_PR |
Long-term estimates of cancer incidence and mortality for the EU and EFTA countries according to different demographic scenarios |
Abstract + full data set: Thursday, 9 September 2021, 14:00 CEST |
1560O_PR |
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-Cov-2 infection |
Abstract + full data set: Thursday, 9 September 2021, 14:00 CEST |
1489P_PR |
Tunisian children and adolescents coping with parental cancer. |
Abstract: Monday, 13 September 2021, 00:05 CEST Full data set: Thursday, 16 September 2021, 08:30 CEST |
1723P_PR |
Therapeutic nihilism or therapeutic realism: Perceptions of non-oncologist physicians regarding cancer patients’ prognosis |
Abstract: Monday, 13 September 2021, 00:05 CEST Full data set: Thursday, 16 September 2021, 08:30 CEST |
1510MO_PR |
European cancer patients’ perspectives on Immunotherapy |
Abstract: Friday, 17 September 2021, 00:05 CEST Full data set: Saturday, 18 September 2021, 17:30 CEST |
1669O_PR |
Late effects, long-term problems and unmet needs of cancer survivors |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Tuesday, 21 September 2021, 13:30 CEST |
LBA2_PR |
KEYNOTE-826: A randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Saturday, 18 September 2021, 15:05 CEST |
LBA3_PR |
Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Saturday, 18 September 2021, 15:05 CEST |
LBA4_PR |
Abiraterone acetate and prednisolone (AAP) or AAP and enzalutamide (enza) added to androgen deprivation therapy (ADT) for men with high-risk locally advanced prostate cancer (PCa): metastases-free survival (MFS) results from STAMPEDE (NCT00268476) |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Sunday, 19 September 2021, 15:05 CEST |
LBA5_PR |
A phase 3 trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1 |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Sunday, 19 September 2021, 15:05 CEST |
LBA17_PR |
Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Sunday, 19 September 2021, 13:30 CEST |
567O_PR |
FIrst International Randomized STudy in MAlignant Progressive Pheochromocytoma and Paraganliomas (FIRSTMAPPP): an academic double-blind trial investigating Sunitinib |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Monday, 20 September 2021, 15:05 CEST |
Abstracts with a specific release date
Abstract ID |
Title |
Embargo lift |
|---|---|---|
119O |
Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized Phase 3 trial |
Abstract + full data set: Thursday, 9 September 2021, 14:00 CEST |
LBA65 |
First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients with unresectable malignant pleural mesothelioma: 3-year update from CheckMate 743 |
Abstract + full data set: Thursday, 9 September 2021, 14:00 CEST |
1757O |
Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients |
Abstract + full data set: Friday, 17 September 2021, 18:00 CEST |
LBA13 |
Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. Trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial |
Abstract: Friday, 17 September 2021, 00:05 CEST Full data set: Friday, 17 September 2021, 18:00 CEST |
LBA15 |
Primary outcomes of the multi-center multinational randomized phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice combination chemotherapy in patients with pretreated HER2-positive locally advanced or metastatic breast cancer |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Saturday, 18 September 2021, 18:00 CEST |
579MO |
CheckMate 9KD cohort A2 final analysis: nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC) |
Abstract: Friday, 17 September 2021, 00:05 CEST Full data set: Saturday, 18 September 2021, 18:00 CEST |
1123O |
Comprehensive Evaluation of Cell-Free DNA (cfDNA) Multi-Omics for Multi-Cancer Early Detection (MCED) |
Abstract: Saturday, 18 September 2021, 00:05 CEST Full data set: Saturday, 18 September 2021, 18:00 CEST |
Third-party media activities
Media activities initiated by third parties during or in connection with the event are subject to the ESMO Policy on Third-Party Media Activities which aims to guarantee proper and correct distribution of oncology and cancer-related information to media representatives in connection with the conference. Such media activities include (but are not limited to):
- Meetings such as press conferences, media briefings and educational sessions involving media representatives
- PR activities, such as press releases, news, articles, interviews, etc.
Press events concomitant with/or during breaks of the scientific programme of the event are subject to ESMO Press Office approval.
Please submit your request by contacting the ESMO Press Office at media@esmo.org.
Blackout times
During Blackout times any media event initiated by third parties is not allowed.
Friday, 17 September 2021 |
from 12:15 to 18:30 CEST |
Saturday, 18 September 2021 |
from 12:45 to 18:30 CEST |
Sunday, 19 September 2021 |
from 12:45 to 18:30 CEST |
Monday, 20 September 2021 |
from 12:45 to 18:30 CEST |
Tuesday, 21 September 2021 |
from 12:45 to 17:30 CEST |
Wednesday, 22 September 2021 |
from 13:00 to 18:25 CEST |
Contact
ESMO Press Office
E-mail: media@esmo.org